Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 30, 2026Pharmacological ReportsOpen Access

Evaluation of the safety profile of glucagon-like peptide-1 receptor agonists: a focus on thyroid cancer-related adverse events by using the European pharmacovigilance database

View Full Paper
Ask AI
Bookmark
Share

Authors

AAAntonietta AnatrielloUniversity of Campania "Luigi Vanvitelli"VLValerio LiguoriUniversity of Campania "Luigi Vanvitelli"CPCiro PentellaUniversity of Campania "Luigi Vanvitelli"

Discussion

Loading...

Member takes

Implication

Analysis evaluates thyroid cancer-related adverse events in patients using GLP-1 RAs, indicating varied safety profiles.

Key Points

  • This research aims to evaluate the safety profile of GLP-1 receptor agonists concerning thyroid cancer-related adverse events.
  • Analyzed individual case safety reports from the EudraVigilance database between January 2022 and September 2024.
  • Performed disproportionality analysis using reporting odds ratios to assess thyroid cancer-related AEs.
  • Conducted a sensitivity analysis across different therapeutic indications.
  • In total, 34,956 individual case safety reports were analyzed.
  • Semaglutide demonstrated a lower probability of thyroid cancer-related AEs compared to tirzepatide (ROR = 0.54, 95% CI 0.37-0.81, p < 0.05).
  • No significant signals for thyroid cancer AEs were observed across stratified therapeutic groups.

Cite This Study

Anatriello et al. (2026) studied this question.

synapsesocial.com/papers/6a1a82a00307b785094343eahttps://doi.org/10.1007/s43440-026-00864-4
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks2024 · 114 citations
  2. 2Comparison of injective related reactions following ofatumumab and ocrelizumab in patients with multiple sclerosis: data from the European spontaneous reporting system2024 · 8 citations
  3. 3The Use of Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus Does Not Increase the Risk of Pancreatic Cancer: A U.S.-Based Cohort Study2024 · 37 citations
  4. 4GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art2020 · 1,632 citations
  5. 5Glucagon-Like Peptide-1 Receptor Agonists for Chronic Weight Management2023 · 36 citations